Array BioPharma to Present at the Lazard Capital Markets 7th Annual Healthcare Conference

BOULDER, Colo.--(BUSINESS WIRE)-- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the Lazard Capital Markets 7th Annual Healthcare Conference in New York City. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

Event:

    Lazard Capital Markets 7th Annual Healthcare Conference

Presenter:

Robert E. Conway, Chief Executive Officer, Array BioPharma

Date:

Tuesday, November 16, 2010

Time:

1:40 p.m. Eastern Time

Location:

The St. Regis, NY

Webcast:

www.arraybiopharma.com

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. For more information on Array, please go to www.arraybiopharma.com.



CONTACT:

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
[email protected]

KEYWORDS:   United States  North America  Colorado

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.